Faculty of Medicine, Department of Clinical Sciences Lund, Lund University, Respiratory Medicine and Allergology, Lund, Sweden.
Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
J Allergy Clin Immunol Pract. 2021 May;9(5):1960-1968.e4. doi: 10.1016/j.jaip.2020.12.030. Epub 2020 Dec 24.
Asthma is a heterogeneous inflammatory airway disease that continues to cause considerable morbidity across the world, with poor asthma control leading to hospitalizations.
The present study investigated the risk of rehospitalization, mortality, and the management of patients with asthma who had been hospitalized because of an asthma exacerbation.
National Swedish health registries were linked for patients 6 years or older who were admitted to hospital because of asthma (index date) between January 1, 2006, and December 31, 2015. Exacerbations were defined as asthma-related hospitalization, emergency visits, or collection of oral steroids. Patients were followed for rehospitalizations 12 months after the index date, health care resource utilization and treatment for 36 months, and mortality to study end. Regression models for time-to-event analyses were applied to assess risk factors for rehospitalization and mortality.
A total of 15,691 patients (mean age, 51.5 years; 63% females) were included, of whom 1,892 (12%) were rehospitalized for asthma within 12 months. Rehospitalized patients had a markedly increased risk of subsequent asthma-related mortality (adjusted hazard ratio, 2.80; 95% CI, 1.95-4.01) compared with those not rehospitalized. Two-third of the patients were not followed up by a hospital-based specialist, and 60% did not collect enough inhaled corticosteroid doses to cover daily treatment the year postindex.
In this study, more than 1 in 10 patients were rehospitalized because of asthma within 12 months, and rehospitalizations were associated with asthma-related mortality. Few patients were seen by a hospital-based specialist, and few used inhaled corticosteroid continuously. Closer monitoring after hospitalization is needed.
哮喘是一种异质性炎症性气道疾病,在全球范围内仍导致相当高的发病率,哮喘控制不佳会导致住院治疗。
本研究调查了因哮喘加重而住院的哮喘患者再次住院、死亡的风险,以及这些患者的管理情况。
将年龄在 6 岁及以上的、2006 年 1 月 1 日至 2015 年 12 月 31 日期间因哮喘住院的患者的国家瑞典健康登记数据进行了关联。哮喘加重的定义为与哮喘相关的住院治疗、急诊就诊或口服类固醇药物的使用。从索引日期起,对患者进行了 12 个月的再次住院、36 个月的健康护理资源利用和治疗以及研究结束时的死亡随访。应用时间事件分析回归模型评估再次住院和死亡的风险因素。
共纳入 15691 例患者(平均年龄 51.5 岁,63%为女性),其中 1892 例(12%)在 12 个月内因哮喘再次住院。与未再次住院的患者相比,再次住院的患者有明显更高的后续哮喘相关死亡率的风险(调整后的危险比,2.80;95%置信区间,1.95-4.01)。三分之二的患者未由医院专科医生进行随访,并且 60%的患者在索引后一年未使用足够的吸入皮质激素剂量来覆盖每日治疗。
在这项研究中,超过 10%的患者在 12 个月内因哮喘再次住院,并且再次住院与哮喘相关的死亡率相关。很少有患者由医院专科医生进行治疗,并且很少有患者持续使用吸入皮质激素。需要在出院后进行更密切的监测。